Reported

An Interview with Chairman Tse-Wen Chang, Founder of Immunwork and T-E Meds: A Journey Through Science and Entrepreneurship

Dr. Tse-Wen Chang, Chairman and Founder of Immunwork and T-E Meds, built his scientific career through National Tsing-Hua University, Harvard University, and the Massachusetts Institute of Technology (MIT), and went on to lead the development of Xolair, the world’s first anti-IgE drug—marking a groundbreaking milestone in the treatment of allergies and asthma. After achieving remarkable […]

An Interview with Chairman Tse-Wen Chang, Founder of Immunwork and T-E Meds: A Journey Through Science and Entrepreneurship Read More »

Immunwork Spotlight: TE-8214 — A Long-Acting Drug Revolution from “Maltose” to “Aqueous Solution”

In 2025, Immunwork successfully reached key clinical trial milestones for two drug candidates, TE-8105 and TE-8214. In an exclusive interview with Lifestyle Forum, Chairman Tse-Wen Chang highlighted the innovative drug design of TE-8214 and its potential breakthrough applications in clinical settings. Looking ahead to 2026, Immunwork will initiate the next phases of clinical trials for

Immunwork Spotlight: TE-8214 — A Long-Acting Drug Revolution from “Maltose” to “Aqueous Solution” Read More »

In-Depth Interview with Chairman Tse-Wen Chang: Leading T-E Meds in Advancing ADC Technology

T-E Meds has distinguished itself from a highly competitive pool of global nominees and has been selected as one of only six companies worldwide to be shortlisted for the “Best New Drug Developer 2025” category at the 12th World ADC Awards. This recognition highlights T-E Meds’ outstanding achievements in ADC technology platforms and innovative drug

In-Depth Interview with Chairman Tse-Wen Chang: Leading T-E Meds in Advancing ADC Technology Read More »

The 2024 Tang Prize is awarded to three scientists for the development of GLP-1

The 2024 Tang Prize in Biopharmaceutical Science has cast a spotlight on GLP-1 receptor agonists, sparking a global race among pharmaceutical companies. TE-8105 of Immunwork, an ultra-long-acting GLP-1 drug, is set to initiate its Phase I clinical trial in Australia, promising significant potential for future development! News website link: 1. https://www.chinatimes.com/newspapers/20240624000185-260202?utm_source=iii_news&utm_medium=rss&chdtv 2. https://www.chinatimes.com/newspapers/20240620000187-260202?chdtv

The 2024 Tang Prize is awarded to three scientists for the development of GLP-1 Read More »

FDA approves Xolair as first and only medicine for children and adults with one or more food allergies

Congratulations to our founder, Dr. Tse-Wen Chang, the inventor of Xolair.We are thrilled to learn that Xolair’s potential benefits are extending to more patients, especially those with food allergies. The website link: https://www.businesswire.com/news/home/20240215550080/en/FDA-Approves-Xolair-as-First-and-Only-Medicine-for-Children-and-Adults-With-One-or-More-Food-Allergies

FDA approves Xolair as first and only medicine for children and adults with one or more food allergies Read More »

【Reported by Taiwan Global Bio Monthly】The president – Dr. Tse-Wen Chang presents the Immunwork’s latest progress in the 40th anniversary activities of Development Center for Biotechnology (DCB)

Website link: https://news.gbimonthly.com/tw/article/show.php?num=60662&utm_source=dable

【Reported by Taiwan Global Bio Monthly】The president – Dr. Tse-Wen Chang presents the Immunwork’s latest progress in the 40th anniversary activities of Development Center for Biotechnology (DCB) Read More »

Scroll to Top